Claims
- 1. A compound of formula I, or a salt thereof: whereinY represents hydrogen, C1-6 alkyl, amino, C1-6 alkylamino or di(C1-6)alkylamino; and Z represents hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, C6-8 bicycloalkyl, aryl, C3-7 heterocycloalkyl, heteroaryl, C2-7 alkoxycarbonyl or di(C1-6)alkylamino, any of which groups may be optionally substituted, with the proviso that Y and Z are not both simultaneously hydrogen; or Y and Z are taken together with the two intervening carbon atoms to form a ring selected from C5-9 cycloalkenyl, C6-10 bicycloalkenyl, tetrahydropyridinyl, pyridinyl and phenyl, any of which rings may be optionally benzo-fused and/or substituted; R1 represents C3-7 cycloalkyl, phenyl, furyl, thienyl or pyridinyl, any of which groups may be optionally substituted; and R2 represents C3-7 cycloalkyl(C1-6)alkyl, aryl(C1-6)alkyl or heteroaryl(C1-6)alkyl, any of which groups may be optionally substituted.
- 2. A compound as claimed in claim 1 represented by formula IIA, and salts thereof: whereinR5 represents hydrogen, methyl, ethyl or n-propyl.
- 3. A compound as claimed in claim 2 represented by formula IIB, and pharmaceutically acceptable salts thereof:
- 4. A compound as claimed in claim 2 represented by formula IIC, and pharmaceutically acceptable salts thereof: whereinZ1 represents C1-6 alkyl or C3-7 cycloalkyl.
- 5. A compound as claimed in claim 2 represented by formula IID, and pharmaceutically acceptable salts thereof: whereinR13 represents hydrogen or halogen.
- 6. A compound selected from:5-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-3-phenyl-3H-pyrazolo[3,4-c]isoquinoline; 5-(2-ethyl-2H-[1,2,4]triazol-3-ylmethoxy)-3-phenyl-3H-pyrazolo[3,4-c]isoquinoline; 5-(1,1-dimethylethyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-1-phenyl-1H-pyrazolo[3,4-b]pyridine; 5-(1,1-dimethylethyl)-6-(2-ethyl-2H-[1,2,4]triazol-3-ylmethoxy)-1-phenyl-1H-pyrazolo[3,4-b]pyridine; 5-methyl-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-1-phenyl-1H-pyrazolo[3,4-b]pyridine; 6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-ylamine; and salts and prodrugs thereof.
- 7. A pharmaceutical composition comprising a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.
- 8. A method for the treatment or prevention of anxiety which comprises administering to a patient in need of such treatment an effective amount of a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof.
- 9. A process for the preparation of a compound of formula I as defined in claim 1, which comprises:(A) reacting a compound of formula III with a compound of formula IV: wherein Y, Z, R1 and R2 are as defined in claim 1, and L1 represents a suitable leaving group; or(B) reacting a compound of formula XI with a compound of formula XII: wherein Y, Z, R1 and R2 are as defined in claim 1, and L2 represents a suitable leaving group; or(C) reacting a compound of formula XIII with a compound of formula XIV: wherein Y, Z, R1 and R2 are as defined in claim 1, and E represents the residue of an organometallic reagent, or E represents —B(OH)2; in the presence of a transition metal catalyst; and(D) subsequently, if desired, converting a compound of formula I initially obtained into a further compound of formula I.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9929685 |
Dec 1999 |
GB |
|
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a U.S. National Phase application under 35 U.S.C. §371 of PCT Application No. PCT/GB00/04652, filed Dec. 5, 2000, which claims priority under 35 U.S.C. §119 from GB Application No. 9929685.7, filed Dec. 15, 1999.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/GB00/04652 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO01/44244 |
6/21/2001 |
WO |
A |
Foreign Referenced Citations (4)
Number |
Date |
Country |
WO 9900391 |
Jan 1999 |
WO |
WO 9906399 |
Feb 1999 |
WO |
WO 9937644 |
Jul 1999 |
WO |
WO 9948892 |
Sep 1999 |
WO |